Effects of Aripiprazole on Olanzapine Population Pharmacokinetics and Initial Dosage Optimization in Schizophrenia Patients

References

• Jauhar S, Johnstone M, McKenna PJ. Schizophrenia. Lancet. 2022;399(10323):473–486. doi:10.1016/s0140-6736(21)01730-x
   PubMed Web of Science ®Google Scholar
• Srivastava A, Dada O, Qian J, et al. Epigenetics of schizophrenia. Psychiatry Res. 2021;305:114218. doi:10.1016/j.psychres.2021.114218
   PubMed Web of Science ®Google Scholar
• Messias EL, Chen CY, Eaton WW. Epidemiology of schizophrenia: review of findings and myths. Psychiatr Clin North Am. 2007;30(3):323–338. doi:10.1016/j.psc.2007.04.007
   PubMed Web of Science ®Google Scholar
• Kowalski K, Zebrowska-Rozanska P, Karpinski P, et al. Profiling gut microbiota signatures associated with the deficit subtype of schizophrenia: findings from a case-control study. Prog Neuropsychopharmacol Biol Psychiatry. 2023;127:110834. doi:10.1016/j.pnpbp.2023.110834
   PubMed Web of Science ®Google Scholar
• Xiong Z, Wang H, Qu Y, et al. The mitochondria in schizophrenia with 22q11.2 deletion syndrome: from pathogenesis to therapeutic promise of targeted natural drugs. Prog Neuropsychopharmacol Biol Psychiatry. 2023;127:110831. doi:10.1016/j.pnpbp.2023.110831
   PubMed Web of Science ®Google Scholar
• Zhilyaeva TV, Kasyanov ED, Rukavishnikov GV, et al. Pterin metabolism, inflammation and oxidative stress biochemical markers in schizophrenia: factor analysis and assessment of clinical symptoms associations. Prog Neuropsychopharmacol Biol Psychiatry. 2023;127:110823. doi:10.1016/j.pnpbp.2023.110823
   PubMed Web of Science ®Google Scholar
• Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1999;20(3):201–225. doi:10.1016/S0893-133X(98)00060-8
   PubMed Web of Science ®Google Scholar
• de Bartolomeis A, Ciccarelli M, De Simone G, Mazza B, Barone A, Vellucci L. Canonical and non-canonical antipsychotics’ dopamine-related mechanisms of present and next generation molecules: a systematic review on translational highlights for treatment response and treatment-resistant schizophrenia. Int J Mol Sci. 2023;24(6). doi:10.3390/ijms24065945
   Web of Science ®Google Scholar
• Lu Z, Zhang Y, Sun Y, et al. Therapeutic outcomes wide association scan of different antipsychotics in patients with schizophrenia: randomized clinical trials and multi-ancestry validation. Psychiatry Clin Neurosci. 2023;77(9):486–496. doi:10.1111/pcn.13567
   PubMed Web of Science ®Google Scholar
• Bahta M, Ogbaghebriel A, Russom M, Tesfamariam EH, Berhe T. Impact of adverse reactions to first-generation antipsychotics on treatment adherence in outpatients with schizophrenia: a cross-sectional study. Ann Gen Psychiatry. 2021;20(1):27. doi:10.1186/s12991-021-00348-0
   PubMed Web of Science ®Google Scholar
• Mutwalli H, Keeler JL, Bektas S, Dhopatkar N, Treasure J, Himmerich H. Eating cognitions, emotions and behaviour under treatment with second generation antipsychotics: a systematic review and meta-analysis. J Psychiatr Res. 2023;160:137–162. doi:10.1016/j.jpsychires.2023.02.006
   PubMed Web of Science ®Google Scholar
• Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs. 2004;18(4):251–267. doi:10.2165/00023210-200418040-00005
   PubMed Web of Science ®Google Scholar
• Cepaityte D, Siafis S, Papazisis G. Safety of antipsychotic drugs: a systematic review of disproportionality analysis studies. Behav Brain Res. 2021;404:113168. doi:10.1016/j.bbr.2021.113168
   PubMed Web of Science ®Google Scholar
• Soria-Chacartegui P, Villapalos-Garcia G, Zubiaur P, Abad-Santos F, Koller D. Genetic polymorphisms associated with the pharmacokinetics, pharmacodynamics and adverse effects of olanzapine, aripiprazole and risperidone. Front Pharmacol. 2021;12:711940. doi:10.3389/fphar.2021.711940
   PubMed Web of Science ®Google Scholar
• Zhao L, Liu H, Wang W, Wang Y, Xiu M, Li S. Carnitine metabolites and cognitive improvement in patients with schizophrenia treated with olanzapine: a prospective longitudinal study. Front Pharmacol. 2023;14:1255501. doi:10.3389/fphar.2023.1255501
   PubMed Web of Science ®Google Scholar
• Ding J, Zhang Y, Zhang Y, et al. Effects of age, sex, and comedication on the plasma concentrations of olanzapine in Chinese patients with schizophrenia based on therapeutic drug monitoring data. J Clin Psychopharmacol. 2022;42(6):552–559. doi:10.1097/JCP.0000000000001618
   PubMed Web of Science ®Google Scholar
• Karwautz A, Zeiler M, Schwarzenberg J, et al. Therapeutic drug monitoring in adolescents with anorexia nervosa for safe treatment with adjunct olanzapine. Eur Eat Disord Rev. 2023. doi:10.1002/erv.3022
   Web of Science ®Google Scholar
• Miroshnichenko II, Pozhidaev IV, Ivanova SA, Baymeeva NV. Therapeutic drug monitoring of olanzapine and cytochrome P450 genotyping in nonsmoking subjects. Ther Drug Monit. 2020;42(2):325–329. doi:10.1097/FTD.0000000000000695
   PubMed Web of Science ®Google Scholar
• Xiao T, Wang Z, Li G, et al. What to do about missed doses? A retrospective study of olanzapine in the elderly. Drug Des Devel Ther. 2021;15:3411–3423. doi:10.2147/DDDT.S316110
   PubMed Web of Science ®Google Scholar
• Zhu X, Hu J, Xiao T, Huang S, Wen Y, Shang D. An interpretable stacking ensemble learning framework based on multi-dimensional data for real-time prediction of drug concentration: the example of olanzapine. Front Pharmacol. 2022;13:975855. doi:10.3389/fphar.2022.975855
   PubMed Web of Science ®Google Scholar
• Iwahashi K. Olanzapine metabolism by CYP1A2/CYP2D6 and hyperglycaemia. Acta Neuropsychiatr. 2004;16(4):229–230. doi:10.1111/j.0924-2708.2004.00089.x
   PubMed Web of Science ®Google Scholar
• Rojas-Macetas A, Medalla-Garro G, Saravia M, et al. Potential polymorphic CYP1A2 and CYP2D6-mediated pharmacokinetic interactions between risperidone or olanzapine and selected drugs intended to treat COVID-19. Drug Metab Bioanal Lett. 2022. doi:10.2174/1872312815666221125112724
   PubMedGoogle Scholar
• Xin Y, Gao L, Tuo Y, et al. Understanding inter-individual variability in pharmacokinetics/pharmacodynamics of aripiprazole in children with tic disorders: individualized administration based on physiological development and CYP2D6 genotypes. Front Pharmacol. 2022;13:1048498. doi:10.3389/fphar.2022.1048498
   PubMed Web of Science ®Google Scholar
• Islam F, Marshe VS, Magarbeh L, et al. Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study. Transl Psychiatry. 2022;12(1):366. doi:10.1038/s41398-022-02124-4
   PubMed Web of Science ®Google Scholar
• Kneller LA, Zubiaur P, Koller D, Abad-Santos F, Hempel G. Influence of CYP2D6 phenotypes on the pharmacokinetics of aripiprazole and dehydro-aripiprazole using a physiologically based pharmacokinetic approach. Clin Pharmacokinet. 2021;60(12):1569–1582. doi:10.1007/s40262-021-01041-x
   PubMed Web of Science ®Google Scholar
• Xiu M, Zhao L, Sun Q, Lang X. Efficacy of low-dose olanzapine in combination with sertraline on negative symptoms and psychosocial functioning in schizophrenia: a randomized controlled trial. Curr Neuropharmacol. 2023. doi:10.2174/1570159X21666230913152344
   Google Scholar
• Brothwood PL, Husain M, Pinson J, Oloyede E, Davey P, Whiskey E. Clozapine in combination with olanzapine long-acting injection: the intersection of treatment-resistant schizophrenia and poor medication adherence-a case report. J Clin Psychopharmacol. 2023;43(5):472–474. doi:10.1097/JCP.0000000000001746
   PubMed Web of Science ®Google Scholar
• Liu JL, Tan ZM, Jiao SJ. Repetitive transcranial magnetic stimulation combined with olanzapine and amisulpride for treatment-refractory schizophrenia. World J Psychiatry. 2023;13(7):453–460. doi:10.5498/wjp.v13.i7.453
   PubMed Web of Science ®Google Scholar
• Sun L, Mills R, Sadler BM, Rege B. Population pharmacokinetics of olanzapine and samidorphan when administered in combination in healthy subjects and patients with schizophrenia. J Clin Pharmacol. 2021;61(11):1430–1441. doi:10.1002/jcph.1911
   PubMed Web of Science ®Google Scholar
• Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303–332. doi:10.1146/annurev.pharmtox.48.113006.094708
   PubMed Web of Science ®Google Scholar
• Horacek J, Bubenikova-Valesova V, Kopecek M, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20(5):389–409. doi:10.2165/00023210-200620050-00004
   PubMed Web of Science ®Google Scholar
• Komossa K, Rummel-Kluge C, Hunger H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;(3):CD006654. doi:10.1002/14651858.CD006654.pub2
   PubMed Web of Science ®Google Scholar
• Ennis C, Kemp JD, Cox B. Characterisation of inhibitory 5-hydroxytryptamine receptors that modulate dopamine release in the striatum. J Neurochem. 1981;36(4):1515–1520. doi:10.1111/j.1471-4159.1981.tb00594.x
   PubMed Web of Science ®Google Scholar
• Matsui-Sakata A, Ohtani H, Sawada Y. Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release. Drug Metab Pharmacokinet. 2005;20(3):187–199. doi:10.2133/dmpk.20.187
   PubMedGoogle Scholar
• Mao JH, Han L, Liu XQ, Jiao Z. Significant predictors for olanzapine pharmacokinetics: a systematic review of population pharmacokinetic studies. Expert Rev Clin Pharmacol. 2023;16(6):575–588. doi:10.1080/17512433.2023.2219055
   PubMed Web of Science ®Google Scholar
• Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999;37(3):177–193. doi:10.2165/00003088-199937030-00001
   PubMed Web of Science ®Google Scholar
• Bigos KL, Pollock BG, Coley KC, et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol. 2008;48(2):157–165. doi:10.1177/0091270007310385
   PubMed Web of Science ®Google Scholar
• Beasley CM, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology. 1996;124(1–2):159–167. doi:10.1007/BF02245617
   PubMed Web of Science ®Google Scholar
• Solmi M, Fornaro M, Ostinelli EG, et al. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. World Psychiatry. 2020;19(2):214–232. doi:10.1002/wps.20765
   PubMed Web of Science ®Google Scholar
• Shen X, Chen X, Lu J, et al. Pharmacogenetics-based population pharmacokinetic analysis and dose optimization of valproic acid in Chinese southern children with epilepsy: effect of ABCB1 gene polymorphism. Front Pharmacol. 2022;13:1037239. doi:10.3389/fphar.2022.1037239
   PubMed Web of Science ®Google Scholar
• Thyssen A, Vermeulen A, Fuseau E, Fabre MA, Mannaert E. Population pharmacokinetics of oral risperidone in children, adolescents and adults with psychiatric disorders. Clin Pharmacokinet. 2010;49(7):465–478. doi:10.2165/11531730-000000000-00000
   PubMed Web of Science ®Google Scholar
• Chen CY, Zhou Y, Cui YM, Yang T, Zhao X, Wu Y. Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy. J Clin Pharm Therapeutics. 2019;44(2):300–311. doi:10.1111/jcpt.12792
   PubMed Web of Science ®Google Scholar
• Wang ZZ, Zhang YF, Huang WC, et al. Effects of comedication and genetic factors on the population pharmacokinetics of lamotrigine: a prospective analysis in Chinese patients with epilepsy. Front Pharmacol. 2019;10:832. doi:10.3389/fphar.2019.00832
   PubMed Web of Science ®Google Scholar
• Hirose T, Mamiya N, Yamada S, Taguchi M, Kameya T, Kikuchi T. The antipsychotic drug aripiprazole (abilify). Nihon Yakurigaku Zasshi. 2006;128(5):331–345. doi:10.1254/fpj.128.331
   PubMedGoogle Scholar
• Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63(9):763–771. doi:10.4088/jcp.v63n0903
   PubMed Web of Science ®Google Scholar
• Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry. 2007;164(9):1411–1417. doi:10.1176/appi.ajp.2007.06091479
   PubMed Web of Science ®Google Scholar
• Sarkisyan G, Roberts AJ, Hedlund PB. The 5-HT(7) receptor as a mediator and modulator of antidepressant-like behavior. Behav Brain Res. 2010;209(1):99–108. doi:10.1016/j.bbr.2010.01.022
   PubMed Web of Science ®Google Scholar
• Fraguas D, Almenta Gallego D, Arques-Egea S, et al. Aripiprazole for the treatment of schizophrenia: recommendations of a panel of Spanish experts on its use in clinical practice. Int J Psychiatry Clin Pract. 2022:1–10. doi:10.1080/13651501.2022.2064308
   Web of Science ®Google Scholar